Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds
Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chine...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Nie X [verfasserIn] Chen Z [verfasserIn] Pang L [verfasserIn] Wang L [verfasserIn] Jiang H [verfasserIn] Chen Y [verfasserIn] Zhang Z [verfasserIn] Fu C [verfasserIn] Ren B [verfasserIn] Zhang J [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: International Journal of Nanomedicine - Dove Medical Press, 2018, (2020), Seite 10215-10240 |
|---|---|
| Übergeordnetes Werk: |
year:2020 ; pages:10215-10240 |
| Links: |
|---|
| Katalog-ID: |
DOAJ063270552 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ063270552 | ||
| 003 | DE-627 | ||
| 005 | 20230309025813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ063270552 | ||
| 035 | |a (DE-599)DOAJb845915da57e49e2b47684a6b435e584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Nie X |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects | ||
| 650 | 4 | |a type 2 diabetes mellitus (t2dm) | |
| 650 | 4 | |a phytocompounds | |
| 650 | 4 | |a drug delivery systems | |
| 650 | 4 | |a nanoparticles (nps) | |
| 650 | 4 | |a antidiabetic effects | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Chen Z |e verfasserin |4 aut | |
| 700 | 0 | |a Pang L |e verfasserin |4 aut | |
| 700 | 0 | |a Wang L |e verfasserin |4 aut | |
| 700 | 0 | |a Jiang H |e verfasserin |4 aut | |
| 700 | 0 | |a Chen Y |e verfasserin |4 aut | |
| 700 | 0 | |a Zhang Z |e verfasserin |4 aut | |
| 700 | 0 | |a Fu C |e verfasserin |4 aut | |
| 700 | 0 | |a Ren B |e verfasserin |4 aut | |
| 700 | 0 | |a Zhang J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Nanomedicine |d Dove Medical Press, 2018 |g (2020), Seite 10215-10240 |w (DE-627)537879560 |w (DE-600)2377464-2 |x 11782013 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g pages:10215-10240 |
| 856 | 4 | 0 | |u https://doaj.org/article/b845915da57e49e2b47684a6b435e584 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1178-2013 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |j 2020 |h 10215-10240 | ||
| author_variant |
n x nx c z cz p l pl w l wl j h jh c y cy z z zz f c fc r b rb z j zj |
|---|---|
| matchkey_str |
article:11782013:2020----::rlaorgeieyytmfrhtetetfyedaeemliuaaalbediitaint |
| hierarchy_sort_str |
2020 |
| callnumber-subject-code |
R |
| publishDate |
2020 |
| allfields |
(DE-627)DOAJ063270552 (DE-599)DOAJb845915da57e49e2b47684a6b435e584 DE-627 ger DE-627 rakwb eng R5-920 Nie X verfasserin aut Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects type 2 diabetes mellitus (t2dm) phytocompounds drug delivery systems nanoparticles (nps) antidiabetic effects Medicine (General) Chen Z verfasserin aut Pang L verfasserin aut Wang L verfasserin aut Jiang H verfasserin aut Chen Y verfasserin aut Zhang Z verfasserin aut Fu C verfasserin aut Ren B verfasserin aut Zhang J verfasserin aut In International Journal of Nanomedicine Dove Medical Press, 2018 (2020), Seite 10215-10240 (DE-627)537879560 (DE-600)2377464-2 11782013 nnns year:2020 pages:10215-10240 https://doaj.org/article/b845915da57e49e2b47684a6b435e584 kostenfrei https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN kostenfrei https://doaj.org/toc/1178-2013 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 10215-10240 |
| spelling |
(DE-627)DOAJ063270552 (DE-599)DOAJb845915da57e49e2b47684a6b435e584 DE-627 ger DE-627 rakwb eng R5-920 Nie X verfasserin aut Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects type 2 diabetes mellitus (t2dm) phytocompounds drug delivery systems nanoparticles (nps) antidiabetic effects Medicine (General) Chen Z verfasserin aut Pang L verfasserin aut Wang L verfasserin aut Jiang H verfasserin aut Chen Y verfasserin aut Zhang Z verfasserin aut Fu C verfasserin aut Ren B verfasserin aut Zhang J verfasserin aut In International Journal of Nanomedicine Dove Medical Press, 2018 (2020), Seite 10215-10240 (DE-627)537879560 (DE-600)2377464-2 11782013 nnns year:2020 pages:10215-10240 https://doaj.org/article/b845915da57e49e2b47684a6b435e584 kostenfrei https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN kostenfrei https://doaj.org/toc/1178-2013 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 10215-10240 |
| allfields_unstemmed |
(DE-627)DOAJ063270552 (DE-599)DOAJb845915da57e49e2b47684a6b435e584 DE-627 ger DE-627 rakwb eng R5-920 Nie X verfasserin aut Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects type 2 diabetes mellitus (t2dm) phytocompounds drug delivery systems nanoparticles (nps) antidiabetic effects Medicine (General) Chen Z verfasserin aut Pang L verfasserin aut Wang L verfasserin aut Jiang H verfasserin aut Chen Y verfasserin aut Zhang Z verfasserin aut Fu C verfasserin aut Ren B verfasserin aut Zhang J verfasserin aut In International Journal of Nanomedicine Dove Medical Press, 2018 (2020), Seite 10215-10240 (DE-627)537879560 (DE-600)2377464-2 11782013 nnns year:2020 pages:10215-10240 https://doaj.org/article/b845915da57e49e2b47684a6b435e584 kostenfrei https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN kostenfrei https://doaj.org/toc/1178-2013 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 10215-10240 |
| allfieldsGer |
(DE-627)DOAJ063270552 (DE-599)DOAJb845915da57e49e2b47684a6b435e584 DE-627 ger DE-627 rakwb eng R5-920 Nie X verfasserin aut Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects type 2 diabetes mellitus (t2dm) phytocompounds drug delivery systems nanoparticles (nps) antidiabetic effects Medicine (General) Chen Z verfasserin aut Pang L verfasserin aut Wang L verfasserin aut Jiang H verfasserin aut Chen Y verfasserin aut Zhang Z verfasserin aut Fu C verfasserin aut Ren B verfasserin aut Zhang J verfasserin aut In International Journal of Nanomedicine Dove Medical Press, 2018 (2020), Seite 10215-10240 (DE-627)537879560 (DE-600)2377464-2 11782013 nnns year:2020 pages:10215-10240 https://doaj.org/article/b845915da57e49e2b47684a6b435e584 kostenfrei https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN kostenfrei https://doaj.org/toc/1178-2013 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 10215-10240 |
| allfieldsSound |
(DE-627)DOAJ063270552 (DE-599)DOAJb845915da57e49e2b47684a6b435e584 DE-627 ger DE-627 rakwb eng R5-920 Nie X verfasserin aut Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects type 2 diabetes mellitus (t2dm) phytocompounds drug delivery systems nanoparticles (nps) antidiabetic effects Medicine (General) Chen Z verfasserin aut Pang L verfasserin aut Wang L verfasserin aut Jiang H verfasserin aut Chen Y verfasserin aut Zhang Z verfasserin aut Fu C verfasserin aut Ren B verfasserin aut Zhang J verfasserin aut In International Journal of Nanomedicine Dove Medical Press, 2018 (2020), Seite 10215-10240 (DE-627)537879560 (DE-600)2377464-2 11782013 nnns year:2020 pages:10215-10240 https://doaj.org/article/b845915da57e49e2b47684a6b435e584 kostenfrei https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN kostenfrei https://doaj.org/toc/1178-2013 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 10215-10240 |
| language |
English |
| source |
In International Journal of Nanomedicine (2020), Seite 10215-10240 year:2020 pages:10215-10240 |
| sourceStr |
In International Journal of Nanomedicine (2020), Seite 10215-10240 year:2020 pages:10215-10240 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
type 2 diabetes mellitus (t2dm) phytocompounds drug delivery systems nanoparticles (nps) antidiabetic effects Medicine (General) |
| isfreeaccess_bool |
true |
| container_title |
International Journal of Nanomedicine |
| authorswithroles_txt_mv |
Nie X @@aut@@ Chen Z @@aut@@ Pang L @@aut@@ Wang L @@aut@@ Jiang H @@aut@@ Chen Y @@aut@@ Zhang Z @@aut@@ Fu C @@aut@@ Ren B @@aut@@ Zhang J @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
537879560 |
| id |
DOAJ063270552 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ063270552</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309025813.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ063270552</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJb845915da57e49e2b47684a6b435e584</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nie X</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People&rsquo;s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People&rsquo;s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">type 2 diabetes mellitus (t2dm)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phytocompounds</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug delivery systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanoparticles (nps)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antidiabetic effects</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chen Z</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pang L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wang L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jiang H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chen Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhang Z</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fu C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ren B</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhang J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Nanomedicine</subfield><subfield code="d">Dove Medical Press, 2018</subfield><subfield code="g">(2020), Seite 10215-10240</subfield><subfield code="w">(DE-627)537879560</subfield><subfield code="w">(DE-600)2377464-2</subfield><subfield code="x">11782013</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:10215-10240</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/b845915da57e49e2b47684a6b435e584</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-2013</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">10215-10240</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Nie X |
| spellingShingle |
Nie X misc R5-920 misc type 2 diabetes mellitus (t2dm) misc phytocompounds misc drug delivery systems misc nanoparticles (nps) misc antidiabetic effects misc Medicine (General) Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds |
| authorStr |
Nie X |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)537879560 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
R5-920 |
| illustrated |
Not Illustrated |
| issn |
11782013 |
| topic_title |
R5-920 Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds type 2 diabetes mellitus (t2dm) phytocompounds drug delivery systems nanoparticles (nps) antidiabetic effects |
| topic |
misc R5-920 misc type 2 diabetes mellitus (t2dm) misc phytocompounds misc drug delivery systems misc nanoparticles (nps) misc antidiabetic effects misc Medicine (General) |
| topic_unstemmed |
misc R5-920 misc type 2 diabetes mellitus (t2dm) misc phytocompounds misc drug delivery systems misc nanoparticles (nps) misc antidiabetic effects misc Medicine (General) |
| topic_browse |
misc R5-920 misc type 2 diabetes mellitus (t2dm) misc phytocompounds misc drug delivery systems misc nanoparticles (nps) misc antidiabetic effects misc Medicine (General) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
International Journal of Nanomedicine |
| hierarchy_parent_id |
537879560 |
| hierarchy_top_title |
International Journal of Nanomedicine |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)537879560 (DE-600)2377464-2 |
| title |
Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds |
| ctrlnum |
(DE-627)DOAJ063270552 (DE-599)DOAJb845915da57e49e2b47684a6b435e584 |
| title_full |
Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds |
| author_sort |
Nie X |
| journal |
International Journal of Nanomedicine |
| journalStr |
International Journal of Nanomedicine |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
10215 |
| author_browse |
Nie X Chen Z Pang L Wang L Jiang H Chen Y Zhang Z Fu C Ren B Zhang J |
| class |
R5-920 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Nie X |
| author2-role |
verfasserin |
| title_sort |
oral nano drug delivery systems for the treatment of type 2 diabetes mellitus: an available administration strategy for antidiabetic phytocompounds |
| callnumber |
R5-920 |
| title_auth |
Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds |
| abstract |
Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects |
| abstractGer |
Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects |
| abstract_unstemmed |
Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People’s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| title_short |
Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds |
| url |
https://doaj.org/article/b845915da57e49e2b47684a6b435e584 https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN https://doaj.org/toc/1178-2013 |
| remote_bool |
true |
| author2 |
Chen Z Pang L Wang L Jiang H Chen Y Zhang Z Fu C Ren B Zhang J |
| author2Str |
Chen Z Pang L Wang L Jiang H Chen Y Zhang Z Fu C Ren B Zhang J |
| ppnlink |
537879560 |
| callnumber-subject |
R - General Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
R5-920 |
| up_date |
2024-07-03T16:46:57.111Z |
| _version_ |
1803577162057383936 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ063270552</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309025813.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ063270552</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJb845915da57e49e2b47684a6b435e584</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nie X</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Xin Nie,1 Zhejie Chen,2 Lan Pang,1 Lin Wang,1 Huajuan Jiang,1 Yi Chen,1 Zhen Zhang,1 Chaomei Fu,1 Bo Ren,1 Jinming Zhang1 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People&rsquo;s Republic of China; 2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People&rsquo;s Republic of ChinaCorrespondence: Jinming Zhang; Bo Ren Email cdutcmzjm126.com; renbo@cdutcm.edu.cnAbstract: In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">type 2 diabetes mellitus (t2dm)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phytocompounds</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug delivery systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nanoparticles (nps)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antidiabetic effects</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chen Z</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pang L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wang L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jiang H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chen Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhang Z</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fu C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ren B</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhang J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Nanomedicine</subfield><subfield code="d">Dove Medical Press, 2018</subfield><subfield code="g">(2020), Seite 10215-10240</subfield><subfield code="w">(DE-627)537879560</subfield><subfield code="w">(DE-600)2377464-2</subfield><subfield code="x">11782013</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:10215-10240</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/b845915da57e49e2b47684a6b435e584</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/oral-nano-drug-delivery-systems-for-the-treatment-of-type-2-diabetes-m-peer-reviewed-article-IJN</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-2013</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">10215-10240</subfield></datafield></record></collection>
|
| score |
7.400069 |